This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2005 Jul 14;353(2):207-8.

doi: 10.1056/NEJM200507143530217.

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

Jin-Yuan Shih, Chien-Hung Gow, Pan-Chyr Yang

PMID: 16014893
DOI: 10.1056/NEJM200507143530217

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

Jin-Yuan Shih et al. N Engl J Med. 2005.

. 2005 Jul 14;353(2):207-8.

doi: 10.1056/NEJM200507143530217.

Authors

Jin-Yuan Shih, Chien-Hung Gow, Pan-Chyr Yang

PMID: 16014893
DOI: 10.1056/NEJM200507143530217

No abstract available

PubMed Disclaimer

Similar articles

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. Kosaka T, et al. Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714. Clin Cancer Res. 2006. PMID: 17020982
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Myerson JS, Iqbal SA, O'Brien ME, Popat S. Myerson JS, et al. Clin Lung Cancer. 2010 Sep 1;11(5):E5-8. doi: 10.3816/CLC.2010.n.047. Clin Lung Cancer. 2010. PMID: 20837451
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Morabito A, Costanzo R, Rachiglio AM, Pasquale R, Sandomenico C, Franco R, Montanino A, De Lutio E, Rocco G, Normanno N. Morabito A, et al. J Thorac Oncol. 2013 Jul;8(7):e59-60. doi: 10.1097/JTO.0b013e318286cc26. J Thorac Oncol. 2013. PMID: 23774386 No abstract available.
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE, Minna JD. Dowell JE, et al. Nat Clin Pract Oncol. 2004 Nov;1(1):2-3. doi: 10.1038/ncponc0007. Nat Clin Pract Oncol. 2004. PMID: 16264773 Review. No abstract available.
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF, Reck M. Heigener DF, et al. Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Adv Ther. 2011. PMID: 21181318 Review.

See all similar articles

Cited by

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T, Su C, Ren S, Cappuzzo F, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group. Jiang T, et al. J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61. J Thorac Dis. 2018. PMID: 30174832 Free PMC article. Review.
Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling.
Jacobi N, Seeboeck R, Hofmann E, Schweiger H, Smolinska V, Mohr T, Boyer A, Sommergruber W, Lechner P, Pichler-Huebschmann C, Önder K, Hundsberger H, Wiesner C, Eger A. Jacobi N, et al. Oncotarget. 2017 Nov 17;8(64):107423-107440. doi: 10.18632/oncotarget.22475. eCollection 2017 Dec 8. Oncotarget. 2017. PMID: 29296175 Free PMC article.
MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.
Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li H, Zhang Z. Du J, et al. Tumour Biol. 2016 Mar;37(3):3939-47. doi: 10.1007/s13277-015-4247-8. Epub 2015 Oct 19. Tumour Biol. 2016. PMID: 26482612
Mathematical modeling and computational prediction of cancer drug resistance.
Sun X, Hu B. Sun X, et al. Brief Bioinform. 2018 Nov 27;19(6):1382-1399. doi: 10.1093/bib/bbx065. Brief Bioinform. 2018. PMID: 28981626 Free PMC article. Review.
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.
Wu SG, Yu CJ, Yang JC, Shih JY. Wu SG, et al. Ther Adv Med Oncol. 2020 Aug 10;12:1758835920946156. doi: 10.1177/1758835920946156. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32843903 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal